Tower Research Capital (TRC)’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $47.9K | Buy |
7,467
+664
| +10% | +$4.26K | ﹤0.01% | 3015 |
|
|
2025
Q1 | $24.1K | Sell |
6,803
-39,184
| -85% | -$139K | ﹤0.01% | 2795 |
|
|
2024
Q4 | $174K | Buy |
45,987
+36,347
| +377% | +$137K | ﹤0.01% | 1812 |
|
|
2024
Q3 | $31.2K | Sell |
9,640
-22,296
| -70% | -$72.2K | ﹤0.01% | 2976 |
|
|
2024
Q2 | $60.7K | Buy |
31,936
+21,640
| +210% | +$41.1K | ﹤0.01% | 2947 |
|
|
2024
Q1 | $29.2K | Sell |
10,296
-2,018
| -16% | -$5.73K | ﹤0.01% | 2671 |
|
|
2023
Q4 | $181K | Buy |
12,314
+8,343
| +210% | +$123K | ﹤0.01% | 2184 |
|
|
2023
Q3 | $72.7K | Sell |
3,971
-295
| -7% | -$5.4K | ﹤0.01% | 2237 |
|
|
2023
Q2 | $92K | Buy |
4,266
+2,454
| +135% | +$52.9K | ﹤0.01% | 2066 |
|
|
2023
Q1 | $54K | Sell |
1,812
-86
| -5% | -$2.56K | ﹤0.01% | 2409 |
|
|
2022
Q4 | $70K | Sell |
1,898
-1,160
| -38% | -$42.8K | ﹤0.01% | 2100 |
|
|
2022
Q3 | $86K | Sell |
3,058
-282
| -8% | -$7.93K | ﹤0.01% | 2688 |
|
|
2022
Q2 | $64K | Buy |
3,340
+2,629
| +370% | +$50.4K | ﹤0.01% | 2652 |
|
|
2022
Q1 | $10K | Buy |
+711
| New | +$10K | ﹤0.01% | 4271 |
|